Therapy Areas: Respiratory
Mabwell's B7-H3-targeting ADC clinical trial application receives Chinese regulatory approval
3 April 2025 - Chinese biopharmaceutical company Mabwell (SH:688062) announced on Wednesday that China's National Medical Products Administration (NMPA) has approved the company's novel B7-H...
Dupixent receives approval in Japan as first biologic for COPD treatment
28 March 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Friday that Japan's Ministry of Health, Labour and Welfare has approved Dupixent (dupilumab) f...
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
26 March 2025 - Clinical-stage life science company Vast Therapeutics announced on Tuesday that the US Food and Drug Administration has granted its ALX1 drug candidate 'Qualified Infectious Disea...
Actinium Pharmaceuticals signs Ac-225 radioisotope agreement with Eckert & Ziegler
25 March 2025 - Actinium Pharmaceuticals Inc (NYSE AMERICAN:ATNM), a US-based developer of targeted radiotherapies, announced on Monday that it has signed an agreement with German isotope technology s...
GSK's Nucala (Mepolizumab) COPD application accepted by EMA
24 March 2025 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) announced on Monday that the European Medicines Agency (EMA) has accepted its application to expand the use of Nucala (mepolizu...
Everest Medicines' EVM14 IND application receives US FDA approval
24 March 2025 - Everest Medicines (HKEX 1952.HK), a China-based biopharmaceutical company, announced on Sunday that it has received approval from the US Food and Drug Administration (FDA) for its Inve...